Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response
- 1 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (3) , 361-370
- https://doi.org/10.1097/00002030-200302140-00010
Abstract
Objective: Among treated patients with drug-resistant viremia, structured treatment interruptions often result in the re-emergence of drug-susceptible HIV-1. Theoretically, this may allow for a more durable response to salvage therapy. We therefore studied the long-term treatment outcome to antiretroviral therapy in a cohort of patients who had previously interrupted therapy, focusing on the determinants of treatment success versus failure. Design: A prospective observational study of the response to antiretroviral therapy in patients resuming therapy after a treatment interruption. Virological and immunological studies were performed every month for 3 months and then every 3 months. Results: Twenty-four patients underwent a structured treatment interruption and resumed therapy after a variable period of time (median 20 weeks). The median duration of treatment after the treatment interruption was 109 weeks. A transient virological response was observed in all patients who resumed a regimen containing no drug to which their pre-interruption virus was fully susceptible. Virus isolated during virological failure was genotypically and phenotypically identical to the pre-interruption virus, exhibited reduced replicative capacity, and replicated in vivo at levels similar to the pre-interruption baseline. In contrast, durable viral suppression (< 200 copies/ml) was observed in patients who initiated a regimen containing only one drug to which their pre-interruption virus was fully susceptible. Despite viral suppression, the pre-interruption drug-resistant virus population remained detectable in two patients. Conclusion: Although drug-resistant HIV-1 persists at low levels during and after the interruption of therapy, durable suppression of this virus population may be achieved with a combination regimen containing only one fully active agent.Keywords
This publication has 36 references indexed in Scilit:
- Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment FailureA Randomized TrialJAMA, 2002
- Predictors of Long‐Term Increase in CD4+Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving a Protease Inhibitor–Containing Antiretroviral RegimenThe Journal of Infectious Diseases, 2002
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Phenotypic Drug Susceptibility Testing Predicts Long‐Term Virologic Suppression Better than Treatment History in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2001
- Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359The Journal of Infectious Diseases, 2000
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989